Target ALS 2021 Annual Report
October 4, 2022

Target ALS is pleased to share a copy of our 2021 annual report, which outlines our many expansive and successful activities that advanced ALS research last year. See below for a letter from our founder Dan Doctoroff, followed by a copy of the report.
Dear Friends and Colleagues,
We all hoped we would finally return to normal in 2021. But despite the ongoing challenges caused by the COVID-19 pandemic, I am amazed at what Target ALS has continued to accomplish. We have forged ahead with our funding for breakthrough research; established a one-of-a-kind scientific core; nurtured important new alliances, including across related neurodegenerative diseases; and helped bring more attention to the fight against ALS.
All these encouraging signs came in a year in which I was given a likely ALS diagnosis. As a result, I’ve pulled back from many of my responsibilities so that I can focus on two life-affirming activities: spending more time with friends and family and helping advance ALS research.
We are all working together to create a world in which everyone with an ALS diagnosis lives a long, high-quality life. Thank you for bringing us to a place where the achievement of these goals may be possible.
Yours in this fight against ALS,
Daniel L. Doctoroff
Founder
Related News
What are biomarkers in ALS research?
September 16, 2026
TDP-43: What It Is and Why It Matters in ALS
September 16, 2026
Building the Data Foundation for AI-Driven ALS Drug Discovery
August 25, 2026